1. Home
  2. Sitagliptin
  Subject:

Sitagliptin   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
 Diabetes mellitus type 2 Dipeptidyl peptidase-4 Saxagliptin Hypoglycemia Enzyme inhibitor Dipeptidyl peptidase-4 inhibitor Clinical trial Placebo Metformin Liraglutide Sitagliptin Insulin Obesity Blood sugar Glucose Fasting Diabetes mellitus Protein Apoptosis Gene Western blot Messenger RNA Sulfonylurea Embase PubMed MEDLINE Cochrane Library ClinicalTrials.gov Blood plasma Confidence interval Syndrome Insulin resistance Glucagon-like peptide-1 Cell surface receptor
RELATED SUBJECTS:
The publications listed also have these subjects
Diabetes mellitus type 2  13 times
Dipeptidyl peptidase-4  6 times
Hypoglycemia  5 times
Enzyme inhibitor  5 times
Dipeptidyl peptidase-4 inhibitor  5 times
Clinical trial  5 times
Placebo  4 times
Metformin  4 times
Liraglutide  4 times
Insulin  3 times
Glucagon-like peptide-1 receptor agonist  3 times
Glucagon-like peptide-1  3 times
Blood plasma  3 times
Proteinuria  2 times
Protein  2 times
Insulin glargine  2 times
High-performance liquid chromatography  2 times
Glycated hemoglobin  2 times
Enzyme  2 times
Empagliflozin  2 times
Dopamine  2 times
Cell surface receptor  2 times
Blood sugar  2 times
Bcl-2-associated X protein  2 times
Apoptosis  2 times
Urinary bladder  1 time
Tyrosine hydroxylase  1 time
Triglyceride  1 time
Teaching hospital  1 time
Striatum  1 time
Statin  1 time
Sodium  1 time
Single Center  1 time
Serum albumin  1 time
Serotonin  1 time
Route of administration  1 time
Rotenone  1 time
Rhabdomyolysis  1 time
Retinopathy  1 time
Retinal pigment epithelium  1 time
Retina  1 time
Regression analysis  1 time
PubMed  1 time
Post hoc analysis  1 time
Pioglitazone  1 time
Pharmacokinetics  1 time
Peptide  1 time
Pancreatic cancer  1 time
Oxidative stress  1 time
Nitric oxide  1 time
Nephrotoxicity  1 time
Natriuretic peptide  1 time
Mouse  1 time
Mitral valve  1 time
Metabolite  1 time
Metabolism  1 time
Messenger RNA  1 time
Malondialdehyde  1 time
Low-density lipoprotein  1 time
Lipoprotein  1 time
Lactate dehydrogenase  1 time
Insulin resistance  1 time
Infarction  1 time
Immunofluorescence  1 time
Hypothalamus  1 time
Hyperglycemia  1 time
Homeostasis  1 time
Growth factor  1 time
Glutamic acid  1 time
Glucagon  1 time
Gestational diabetes  1 time
Gastrointestinal tract  1 time
Flow velocity  1 time
Fasting  1 time
Estrogen receptor  1 time
Electroretinography  1 time
Drug interaction  1 time
Disease  1 time
Cyclic adenosine monophosphate  1 time
Creatinine  1 time
Covariance  1 time
Collagen  1 time
ClinicalTrials.gov  1 time
Cisplatin  1 time
Chronic kidney disease  1 time
China  1 time
Carboxylic acid  1 time
C-reactive protein  1 time
Blood urea nitrogen  1 time
Blood lipids  1 time
Bcl-2  1 time
Atorvastatin  1 time
Atherosclerosis  1 time
Astrocyte  1 time
Aspirin  1 time
Artificial intelligence  1 time
Apolipoprotein  1 time
Antioxidant  1 time
Anti-diabetic medication  1 time
Annexin  1 time
Amygdala  1 time
Albumin  1 time
Albinism  1 time
Agonist  1 time
Adiponectin  1 time
Acute kidney injury  1 time
Acetylcholine  1 time
Acarbose  1 time

Publications tagged with this subject: 18

Note: Top 50 publications shown only. Open an item panel to view more info (open all)


1. Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial

2. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

3. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

4. Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

5. Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting

6. Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels

7. Sitagliptin: A Review in Type 2 Diabetes

8. Dipeptidyl Peptidase 4 Inhibitors Diprotin A and Sitagliptin Administered on Weeks 2-3 of Postnatal Development Modulate Monoamine Metabolism in the Striatum of Adult Rats

9. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study

10. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes

11. Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs

12. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

13. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

14. The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis

15. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease

16. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial

17. Sitagliptin exerts anti-apoptotic effect in nephrotoxicity induced by cisplatin in rats

18. Type 2 diabetes and cardiovascular prevention: the dogmas disputed


Questions?

Drop us a message.